Response to neoadjuvant chemotherapy in operable breast carcinoma and conversion of modified radical mastectomy to breast conservation surgery, long term results: an Indian perspective

Kunjan Sharma; Dhruv Sharma; Manoj Gupta; Rajeev Seam; S. S. MInhas

doi:10.18203/2349-2902.isj20172792

Authors

Kunjan Sharma Department of Radiotherapy, IGMC Shimla, Himachal Pradesh, India
Dhruv Sharma Department of Surgery, IGMC Shimla, Himachal Pradesh, India
Manoj Gupta Department of Radiotherapy, IGMC Shimla, Himachal Pradesh, India
Rajeev Seam Department of Radiotherapy, IGMC Shimla, Himachal Pradesh, India
S. S. MInhas Department of Surgery, IGMC Shimla, Himachal Pradesh, India

DOI:

https://doi.org/10.18203/2349-2902.isj20172792

Keywords:

Breast conservation surgery, Clinically complete response, Clinically partial response, Clinically stable disease, Modified radical mastectomy, Neoadjuvant chemotherapy

Abstract

Background: This was a prospective study conducted in a tertiary care hospital over a period of one year w.e.f 01.09.06 to 31.08.07 and included 25 female breast cancer patients who were fine needle aspiration cytology proven. The objective of this study was to observe the response to neoadjuvant chemotherapy (NACT) in T1-T3, N0-N1, M0 patients and to determine the % of patients on whom breast conservation surgery could be performed. Majority of the patients were in 5th or 6th decades of life.

Methods: Thorough clinical examination, bilateral mammography and ultrasound of the diseased breast was performed before administering CAF (cyclophosphamide, doxorubicin and 5-Fluorouracil) based NACT. Majority of the patients received three cycles of NACT. All patients tolerated the treatment well without any severe adverse effects.

Results: Overall 84% of the patients showed response to NACT with 12% showing complete clinical regression of the primary tumour. The incidence of clinically negative axilla increased from 20% to 48% after NACT. The breast conservation surgery (BCS) rate increased from 12% to 64% after NACT.

Conclusions: Of 16 patients who had undergone BCS, one patient had ipsilateral breast recurrence at four years and another one at six years of follow up; that proves the importance and success of BCS in carefully selected patients in our setup.

Metrics

Metrics Loading ...

References

National Cancer Registry Programme. Indian Council of Medical Research. Consolidated report of the population based cancer registries incidence and distribution of cancer, 1990-96. Available at www.ICMR.nic.in/ncrp/cancer reg.pdf.

Richard SC. The Breast, Russel RCG, Norman S, Williams, Bulstrode CJK. Baily and Love’s short practice of Surgery. 24th edition. London NWI 3 BH; published by Hodder Education, 338 Euston Road; 2004:824-846.

Bland KI, Beenken SW, Edward M, Copeland III, The Breast, Brunicardi FC, Anderson DK, Billiar TR, Dunn DL, Hunter JG, Pollock RE. Schwartz Principles of Surgery. 8th edition. NewYork; McGraw Hill Medical Publishing Division; 2005:453-499.

lester SC. The Breast, Abul AK, Kumar V, Nelson F, Robbins and Cotran Pathologic basis of disease. 7th edition. Philadelphia; WB Saunders company; 2004:1119-54.

Laborgne R. Diagnosis of the tumours of the breast by simple roentgenography. Am J Roentgenograph Radium Ther. 1951;65:1-11.

Egan RL. Mammography, Report on 2000 studies. Surg. 1963;53(3):291-302.

Wolfe JN. Mammography, Report on its use in women with breasts abnormal and normal on physical examination. Pro Le Summario Int Lingua. 1964;83:2144-54 .

Iglehart JD, Kaenin CM, Willhemi BJ, Philips LG, The breast, Townsend CM, Beauchamp RD, Evers BM, Mattox KL. Sabiston Text Book of Surgery. The Biological basis of Modern Surgical Practice. 17th edition. Philadelphia; Elsevier; 2000:867-944.

Bland KI, Vezerids MP, Copeland III EM, Breast, Schwartz SI, Shires GT, Spencer FC, Daly JM, Fisher JE, Galloway AC. Principles of Surgery. 7th edition vol 1. NewYork; McGraw Hill Publication; 1999:533-99.

Fisher B, Bryant J, Walmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8):2672-85.

Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, et al. High complete remission rate with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995;13(2):424-9.

Jos A, Hage V, Cornalis JH , de Velde V, Julien JP, Hulin TM, et al. Preoperative chemotherapy in primary operable breast cancer, results from the European organisation for research and treatment of cancer trial 10902. J Clin Oncol. 2001;19(22):4224-37.

Calais G, Berger C, Descamps P, Chapet S, Reynaud Bougnous A, Body G, et al. Conservative treatment feasibility with Induction chemotherapy. Surgery and Radiotherapy for patients with breast carcinoma larger than 3 cm. Cancer. 1994;74:1283-8.

Cholet P, Charrier S, Brian E, Cure H, Van Praagh I, Fellel V, et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Europe J Cancer. 1997;33:862-7.

Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, et al. Surgical conservation planning after neoadjuvant chemotherapy for stage II and Operable Stage III Breast Cancer. Am J Surg. 2001;18(6):601-8.

Powles TJ, Hicklish TF, Markis A. Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995;13(3):547-52.

Forrest AP, levack PA, Chetty U, Hawkins A, Miller WR, Smyth JF, et al. Human tumour model. Lancet. 1986;2(8511):840-2.

Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer, eight year experience at the milan cancer institute. J Clin Oncol. 1998;16(1):93-100.

Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G , Maublanc de MA, et al. Results of neoadjuvant chemotherapy and radiation therapy in breast conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer. 1990;66:119-29.

Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, et al. Primary chemotherapy to avoid mastectomy in tumours with diameters of 3 cm or more. J Natl Cancer Inst. 1990;82(19):1539-45.

Smith IE, Jones AL, O Brien MER, McKinna JA, Sacks N, Baum M, et al. Primary medical chemotherapy for operable breast cancer. Eur J Cancer. 1993;29A:1796-9.

Anderson ED, Forrest AP, Hawkins RA, Anderson TJ, Leonard RC, Chetty U, et al. Primary systemic therapy for operable breast cancer. Br J Cancer. 1991;63(4):561-6.

Kaufman M, Minkwitz GV, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary systemic treatment of operable breast cancer, Review and recommendations. J Clin Oncol. 2003;21(13):2600-8.

Dixon JM, Soon PSH, Breast Conserving Surgery, Fischer JE, Bland KI, Callery MP, Logerfo FW, Clagget GP, Seegar JM. Mastery of Surgery. 5th edition vol. 1, Lippincott Williams and Wilkins Publishers; 2007:502-17.

Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AV, Mirza AN, et al. Accuracy of physical examination, ultrasonography and mammography in predicting residual pathologic tumour size in patients treated with neoadjuvant chemotherapy. Ann Surgery. 2006;243(2):257-64.

Beriwal S, Schwartz GF, Komarnicky L, Giarcia Young JA. Breast conservation therapy after neoadjuvant chemotherapy. Long Term Results. Breast J. 2006;12(2):159-64.

Rouzier R, Jean EM, Carlton M, Falcau M, Soloman A, Forquet A, et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumour recurrence after breast conserving surgery. J Clin Oncol. 2001;19:3828-35.